Related Experiment Videos
Structural basis of inhibitor selectivity in MAP kinases
Z Wang1, B J Canagarajah, J C Boehm
1Department of Biochemistry The University of Texas Southwestern Medical Center at Dallas 5323 Harry Hines Boulevard, Dallas, TX 75235, USA.
Structure (London, England : 1993)
|October 1, 1998
Summary
Structural insights reveal how SB compounds selectively inhibit p38 MAP kinase over ERK2. These findings, based on crystallography, explain the drug specificity and guide the development of new anti-inflammatory and anti-cancer agents.
Area of Science:
- Molecular biology
- Structural biology
- Pharmacology
Background:
- Mitogen-activated protein (MAP) kinases, including p38 and extracellular-signal-regulated kinase 2 (ERK2), are crucial in cellular processes.
- p38 is implicated in inflammation, while ERK2 regulates differentiation and proliferation.
- Selective inhibitors of p38 are sought for therapeutic intervention.
Purpose of the Study:
- To elucidate the structural basis for the selective inhibition of p38 by SB compounds over ERK2.
- To understand the structural basis for olomoucine's selectivity for ERK2.
Main Methods:
- Comparative crystallography was employed.
- Crystal structures of SB compounds with p38 and with ERK2 were determined.
- The crystal structure of olomoucine with ERK2 was also determined.
Main Results:
- SB inhibitors bind to an extended pocket in p38, fitting its open domain structure.
- ERK2's closed domain structure accommodates the smaller olomoucine molecule.
- Differences in active site amino acids and domain interface size contribute to selectivity.
Conclusions:
- Unique kinase-inhibitor interactions explain the selectivity of SB compounds for p38.
- Structural data provides a foundation for designing improved MAP kinase inhibitors.
- This research aids in developing treatments for inflammation and cancer.